EUVIMEDEUVIMED entdecken
Crossref

The Safety and Tolerability of High Dose Intravenous Push Levetiracetam

Melissa Brandes iD, Tara Flack, William B Hays

Journal of Pharmacy Practice · 2025

DOI: 10.1177/08971900251320159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Melissa Brandes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Carle Foundation Hospital, Urbana, IL, USA. Hauptthemen laut MEDLINE: Levetiracetam, Anticonvulsants. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Levetiracetam (LEV) is a guideline-recommended antiepileptic that has been shown to be effective in the termination of status epilepticus. Traditionally, LEV is diluted in 100 mL of compatible fluid and administered as an intravenous (IV) piggyback over 15-60 minutes. Recent data supports the administration of LEV as an undiluted IV push. However, there is limited literature supporting the safety and tolerability of undiluted IV push administration of high dose LEV (2500 mg to 4500 mg). The purpose of this study was to further investigate safety and tolerability of IV push levetiracetam at doses 2500 mg and greater.

Methods

A retrospective chart review was conducted to evaluate adverse drug reactions following IV push administration of levetiracetam at a dose of 2500 mg or greater between the dates 8/5/2021 to 6/30/2022. During chart review, each patient was evaluated for any adverse events that occurred utilizing provider documentation, significant event forms, and/or allergy list documentation following administration of IV push LEV.

Results

Throughout the study period, 340 doses of LEV 2500 mg and greater were evaluated. Most common total dose was 3000 mg and weight-based dose was 50-59.99 mg/kg. 119 doses of 4000 mg or greater were evaluated. 338/340 (99.4%) doses were considered to be well-tolerated. One patient experienced erythema at the injection site and another patient was noted to have nystagmus. Significance: This study adds to the body of literature that rapid administration of undiluted LEV, including doses of 2500 mg to 4500 mg is safe and tolerable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevetiracetamAnticonvulsantsHumansRetrospective StudiesMaleMiddle AgedFemaleDose-Response Relationship, DrugAdultAdministration, IntravenousAged

Stichwörter der Autor:innen

IV pushcritical careemergency medicinelevetiracetam

Substanzen

LevetiracetamAnticonvulsants

Autor:innen und Institutionen

  • Carle Foundation Hospital, Urbana, IL, USA.
  • Indiana University Health Methodist Hospital, Indianapolis, IN, USA.
  • Indiana University Health West Hospital, Avon, IN, USA.

ORCID-Profile: Melissa Brandes

Zitieren

APA

Brandes, M., Flack, T., & Hays, W. B. (2025). The Safety and Tolerability of High Dose Intravenous Push Levetiracetam. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900251320159

Vancouver

Brandes M, Flack T, Hays WB. The Safety and Tolerability of High Dose Intravenous Push Levetiracetam. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900251320159

BibTeX
@article{Brandes2025,
  author = {Brandes, Melissa and Flack, Tara and Hays, William B},
  title = {The Safety and Tolerability of High Dose Intravenous Push Levetiracetam},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  doi = {10.1177/08971900251320159}
}
Kostenlos starten →